The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Open accessPublished version of a preprint
Abstract
SARS-CoV-2 501Y.V2 (B.1.351), a novel lineage of coronavirus causing COVID-19, contains substitutions in two immunodominant domains of the spike protein. Here, we show that pseudovirus expressing 501Y.V2 spike protein completely escapes three classes of therapeutically relevant antibodies. This pseudovirus also exhibits substantial to complete escape from neutralization, but not binding, by convalescent plasma. These data highlight the prospect of reinfection with antigenically distinct variants and foreshadows reduced efficacy of spike-based vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, sera from PIDs who experienced symptomatic SARS-CoV-2 infection and who had detectable anti-RBD IgG titers before vaccination displayed generally weak nAb titers against Wuhan-Hu-1 at 1 to 9 months after infection and lower or nonexistent titers against the B.1.351 variants, in agreement with another study (69).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As previously reported for other vaccines29–33, the neutralizing antibody titres against certain SARS-CoV-2 variants, such as the B.1.351 (Beta) and B.1.617.2 (Delta) variants, were lower than those against the parental strain WA1/2020.”
From Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine (2022) · cites this paper as [32]
Experimental — accuracy not yet measuredIn the citing paper
“recent reports suggest that these variants are partially resistant to neutralization by monoclonal antibodies against spike protein, by convalescent plasma and, notably, by sera from participants who have received severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines91,94,95.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [94]
In the citing paper
“The sensitivity of B.1.351 to neutralizing antibodies from convalescent donors infected with the prototype lineage virus, assessed with a spike-pseudovirus neutralization assay, indicated that 48% of serum samples were unable to neutralize B.1.351, with the rest showing a reduction in neutralization titers by a factor of 3 to 86.21”
From Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [21]
In the citing paper
“In contrast, mutations in B.1.351 and P.1 variants are associated with the more pronounced loss of neutralizing capacity.15,16,22,23,25”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [23]
In the citing paper
“Mutations in the B.1.351and P.1 strains, including E484K and K417N/T, are of high concern, since they partly compromise neutralization generated by previous infection or vaccination [23][24][25] or may increase inherent viral fitness.”
From Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies (2021) · cites this paper as [23]
In the citing paper
“The E484K mutation, which can mediate antibody escape of B.1.351and P.1 variants, has been recently detected in the B.1.1.7 lineage in the United Kingdom, and thus represents a major potential threat for previously immune populations.”
From Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies (2021) · cites this paper as [23]
In the citing paper
“In multiple studies, B.1.351 was the most resistant to neutralization by convalescent or vaccinee sera, with 6- to 15-fold less neutralization activity for sera from individuals immunized with vaccines based on the virus strain first described in January 2020 (Wuhan-Hu-1, spike also called WA1) (2–9).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [6]
In the citing paper
“Most of these prior studies have evaluated sera from vaccinated individuals at time points soon after the first or second dose and have had limited data on the durability of such responses.”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [6]
In the citing paper
“Both the Beta and Delta variants are associated with decreased neutralization by some anti-receptor binding-domain (anti-RBD) and anti-N-terminal domain (anti-NTD) monoclonal antibodies though both Beta and Delta each remain responsive to at least one anti-RBD ( 8 , 9 , 21 ).”
From Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa (2021) · cites this paper as [8]
In the citing paper
“In addition, Beta and Delta are relatively poorly neutralized by convalescent sera obtained from unvaccinated individuals infected with non-VOC virus ( 7 – 9 , 21 ).”
From Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa (2021) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Nextstrain: real-time tracking of pathogen evolutionPreprint
Hadfield, J., Megill, C., Bell, S. M., et al. (2017) · bioRxiv · doi:10.1101/224048 · Cited by 3,172
Nextstrain: real-time tracking of pathogen evolution
Hadfield, J., Megill, C., Bell, S. M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P., Bedford, T., & Neher, R. A. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty407 · Cited by 3,154
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., Yuen, K.-Y., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.045 · Cited by 2,892
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · cited 1×
“N501Y has been shown to increase affinity for the human ACE2 receptor, which together with the repeated and independent evolution of 501Y containing lineages 25,26,31 , strongly argues for enhanced transmissibility of these new variants.”
Self-citationDetection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Self-citation
Cited by
Sorted by citations
Items 601–700 of 1,016
COVID-19 transmission and the safety of air travel during the pandemic: a scoping review
Khatib, A. N., McGuinness, S. L., & Wilder‐Smith, A. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000771 · Cited by 17
Lin, H., Chen, C.-C., Chiao, D.-J., Chang, T.-Y., Chen, X.-A., Young, J., & Kuo, S.-C. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.11.020 · Cited by 17
Lee, M., & Kim, B. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-1621-2 · Cited by 17
Bhattacharjee, R., Dubey, A. K., Ganguly, A., Bhattacharya, B., Mishra, Y. K., Mostafavi, E., & Kaushik, A. K. (2022) · OpenNano · doi:10.1016/j.onano.2022.100078 · Cited by 17
Tigistu‐Sahle, F., Mekuria, Z. H., Satoskar, A. R., Sales, G., Gebreyes, W. A., & de Oliveira, C. J. B. (2023) · Frontiers in Tropical Diseases · doi:10.3389/fitd.2023.1151336 · Cited by 18
Kumar, A., Tripathi, P., Kumar, P., Shekhar, R., & Pathak, R. (2024) · Vaccines · doi:10.3390/vaccines12050459 · Cited by 17
Scialò, F., Vitale, M., Daniele, A., Nigro, E., Perrotta, F., Gelzo, M., Iadevaia, C., Cerqua, F. S., Costigliola, A., Allocca, V., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9060611 · Cited by 17
Oluwagbemi, O. O., Oladipo, E. K., Dairo, E. O., Ayeni, A. E., Irewolede, B. A., Jimah, E. M., Oyewole, M. P., Olawale, B. M., Adegoke, H. M., & Ogunleye, A. J. (2022) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2022.100845 · Cited by 17
Tang, J., Lee, Y., Ravichandran, S., Grubbs, G., Huang, C., Stauft, C. B., Wang, T., Golding, B., Golding, H., & Khurana, S. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2022-222115 · Cited by 17
Petrone, M. E., Rothman, J. E., Breban, M. I., Ott, I. M., Russell, A., Lasek‐Nesselquist, E., Badr, H. S., Kelly, K., Omerza, G., Renzette, N., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03347-3 · Cited by 17
Yurkovetskiy, L., Egri, S. B., Kurhade, C., Díaz-Salinas, M. A., Jaimes, J. A., Nyalile, T., Xie, X., Choudhary, M. C., Dauphin, A., Li, J. Z., et al. (2023) · SSRN Electronic Journal · doi:10.1101/2023.03.30.535005 · Cited by 18
Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America
Quinonez, E., Vahed, M., Shahraki, A. H., & Mirsaeidi, M. S. (2021) · Viruses · doi:10.3390/v13050930 · Cited by 16
Batista, C. M., & Foti, L. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108036 · Cited by 16
Fast SARS-CoV-2 Variant Detection Using Snapback Primer High-Resolution Melting
Lownik, J. C., Farrar, J. S., Way, G. W., McKay, A., Roychoudhury, P., Greninger, A. L., & Martin, R. (2021) · Diagnostics · doi:10.3390/diagnostics11101788 · Cited by 16
Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters
O’Donnell, K. L., Clancy, C. S., Griffin, A. J., Shifflett, K., Gourdine, T., Thomas, T., Long, C. M., Furuyama, W., & Marzi, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.788235 · Cited by 17
The Lived Experience of Postpartum Anxiety During COVID-19: A Hermeneutic Phenomenological Study
Ladd, W., & Decker, J. D. (2022) · The Qualitative Report · doi:10.46743/2160-3715/2022.5420 · Cited by 7
Ramli, S., Wu, Y. S., Batumalaie, K., Guad, R. M., Choy, K. W., Kumar, A., Gopinath, S. C. B., Sarker, M. M. R., Subramaniyan, V., Sekar, M., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11041000 · Cited by 16
Riou, C., Bhiman, J. N., Ganga, Y., Sawry, S., Ayres, F., Baguma, R., Balla, S. R., Benede, N., Bernstein, M. P., Besethi, A. S., et al. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002703 · Cited by 16
Self-citationCohen, M. S., Wohl, D. A., Fischer, W. A., Smith, D. M., & Eron, J. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab494 · Cited by 16
An update on novel approaches for diagnosis and treatment of SARS-CoV-2 infection
Safarchi, A., Fatima, S., Ayati, Z., & Vafaee, F. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00674-6 · Cited by 16
Ferreira, C. D. S., Dantés, H. G., Bellei, N., López, E. L., Crespo, K. A. N., O’Ryan, M., & Villegas, J. (2021) · Viruses · doi:10.3390/v13122391 · Cited by 16
Tan, S. H., Banwell, M. G., Ye, W., Lan, P., & White, L. V. (2022) · Chemistry - An Asian Journal · doi:10.1002/asia.202101215 · Cited by 16
Health system impacts of SARS-CoV − 2 variants of concern: a rapid review
Dol, J., Boulos, L., Somerville, M., Saxinger, L. M., Doroshenko, A., Hastings, S. E., Reynolds, B., Gallant, A. J., Shin, H. D., Wong, H. W. L., et al. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-07847-0 · Cited by 16
Kibria, K. M. K., Faruque, M. O., Islam, M. S. B., Ullah, H., Mahmud, S., Miah, M., & Saleh, A. A. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-11988-x · Cited by 16
Delshad, M., Sanaei, M., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109128 · Cited by 18
Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination
Fryer, H. A., Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E., & van Zelm, M. C. (2022) · Biochemical Society Transactions · doi:10.1042/bst20220415 · Cited by 16
Chen, E. C., Gilchuk, P., Zost, S. J., Ilinykh, P. A., Binshtein, E., Huang, K., Myers, L., Bonissone, S. R., Day, S., Kona, C. R., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112370 · Cited by 16
Bhattacharya, M., Chatterjee, S., Lee, S., Dhama, K., & Chakraborty, C. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101008 · Cited by 16
Wurtzer, S., Waldman, P., Levert, M., Mouchel, J., Gorgé, O., Boni, M., Maday, Y., Maréchal, V., & Moulin, L. (2021) · medRxiv · doi:10.1101/2021.03.10.21253291 · Cited by 16
COVID-19 vaccines: A race against time
Peiffer‐Smadja, N., Rozencwajg, S., Kherabi, Y., Yazdanpanah, Y., & Montravers, P. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100848 · Cited by 16
Muir, L., Jaffer, A., Rees-Spear, C., Gopalan, V., Chang, F. Y., Fernando, R., Vaitkute, G., Roustan, C., Rosa, A., Earl, C. P., et al. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.03.902 · Cited by 15
Effect of time and titer in convalescent plasma therapy for COVID-19
de Candia, P., Prattichizzo, F., Garavelli, S., Grotta, R. L., Rosa, A. D., Pontarelli, A., Parrella, R., Ceriello, A., & Matarese, G. (2021) · iScience · doi:10.1016/j.isci.2021.102898 · Cited by 16
Chaintoutis, S. C., Chassalevris, T., Balaska, S., Mouchtaropoulou, E., Tsiolas, G., Vlatakis, I., Tychala, A., Koutsioulis, D., Argiriou, A., Skoura, L., et al. (2021) · Life · doi:10.3390/life11101015 · Cited by 15
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
Wines, B. D., Kurtovic, L., Trist, H. M., Esparon, S. E., López, E., Chappin, K., Chan, L., Mordant, F. L., Lee, W. S., Gherardin, N. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.889372 · Cited by 15
Learnings from the Australian first few X household transmission project for COVID-19
Marcato, A. J., Black, A. J., Walker, C. R., Morris, D., Meagher, N., Price, D. J., McVernon, J., & the Australian FFX Household Transmission Project Group (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100573 · Cited by 15
A potent, broadly protective vaccine against SARS-CoV-2 variants of concern
Wang, Z., An, J., Liu, K., Yü, P., Fang, X. D., Li, J., Zhu, H., Zhu, Q., Huang, C., Zhang, C., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00571-0 · Cited by 15
Antibody‐mediated control mechanisms of viral infections
Mackin, S., Sariol, A., & Diamond, M. (2024) · Immunological Reviews · doi:10.1111/imr.13383 · Cited by 15
Long COVID across SARS‐CoV‐2 variants: Clinical features, pathogenesis, and future directions
Lok, L. S. C., Sarkar, S., Lam, C. C. I., Law, C., Chau, S. T., Leung, C. Y. T., Cheang, W. H., Li, T., Monteiro, O., & Baptista‐Hon, D. T. (2024) · MedComm – Future Medicine · doi:10.1002/mef2.70004 · Cited by 16
Garritsen, A., Scholzen, A., van den Nieuwenhof, D. W. A., Smits, A. P. F., Datema, E. S., van Galen, L. S., & Kouwijzer, M. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1893378 · Cited by 15
Bukin, Y. S., Bondaryuk, A. N., Kulakova, N. V., Балахонов, С. В., Dzhioev, Y. P., & Zlobin, V. I. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198551 · Cited by 15
Focosi, D., Franchini, M., Joyner, M. J., & Casadevall, A. (2022) · Vox Sanguinis · doi:10.1111/vox.13239 · Cited by 15
Lyski, Z. L., Brunton, A. E., Strnad, M., Sullivan, P. E., Siegel, S. A. R., Tafesse, F., Slifka, M. K., & Messer, W. B. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab585 · Cited by 16
Giron, C. C., Laaksonen, A., & da Silva, F. L. B. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2095305 · Cited by 18
Kimita, G., Nyataya, J., Omuseni, E., Sigei, F., Lemtudo, A. P., Muthanje, E. M., Andika, B., Liyai, R., Githii, R., Masakhwe, C., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00167-8 · Cited by 15
Kruglikov, A., Wei, Y., & Xia, X. (2022) · ACS Omega · doi:10.1021/acsomega.2c04786 · Cited by 16
Beddingfield, B. J., Maness, N. J., Fears, A. C., Rappaport, J., Aye, P. P., Russell‐Lodrigue, K., Doyle‐Meyers, L. A., Blair, R. V., Carias, A. M., Madden, P. J., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.753444 · Cited by 15
Transmission characteristics of SARS-CoV-2 variants of concern Rapid Scoping ReviewPreprint
Curran, J., Dol, J., Boulos, L., Somerville, M., McCulloch, H., Macdonald, M., LeBlanc, J. J., Barrett, L. L., Hatchette, T. F., Comeau, J. L., et al. (2021) · medRxiv · doi:10.1101/2021.04.23.21255515 · Cited by 16
Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity
Tang, H., Gao, L., Wu, Z., Meng, F., Zhao, X., Shao, Y., Shi, X., Qiao, S., An, J., Du, X., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.720357 · Cited by 15
The Potential Roles of BCG Vaccine in the Prevention or Treatment of COVID-19
Wang, J., Zhang, Q., Wang, H., & Gong, W. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2705157 · Cited by 14
Setz, C., Große, M., Auth, J., Fröba, M., Rauch, P., Bausch, A., Wright, M. B., & Schubert, U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126830 · Cited by 15
Anti-COVID-19 Credentials of Chitosan Composites and Derivatives: Future Scope?
Gopal, J., Muthu, M., Pushparaj, S. S. C., & Sivanesan, I. (2023) · Antibiotics · doi:10.3390/antibiotics12040665 · Cited by 14
Motsoeneng, B. M., Manamela, N. P., Kaldine, H., Kgagudi, P., Hermanus, T., Ayres, F., Makhado, Z., Moyo-Gwete, T., van der Mescht, M. A., Abdullah, F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1231276 · Cited by 14
Self-citationA novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations
Zhao, Y., Lee, A., Composto, K., Cunningham, M. H., Mediavilla, J. R., Fennessey, S., Corvelo, A., Chow, K. F., Zody, M. C., Chen, L., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1929504 · Cited by 14
Practical guidance for clinical laboratories for SARS-CoV-2 serology testing
Charlton, C. L., Kanji, J. N., Tran, V., Kus, J. V., Gubbay, J. B., Osiowy, C., Robinson, J. L., Sekirov, I., DREBOT, M. A., Hatchette, T. F., et al. (2021) · Canada Communicable Disease Report · doi:10.14745/ccdr.v47i04a01 · Cited by 14
Jamiruddin, M. R., Haq, M. A., Tomizawa, K., Kobatake, E., Mie, M., Ahmed, S., Khandker, S. S., Ali, T., Jahan, N., Oishee, M. J., et al. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s313188 · Cited by 14
Zamai, L., & Rocchi, M. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15620 · Cited by 14
Liu, J., Chen, Q., Yang, S., Li, Y., Dou, Y., Deng, Y., Bi, J., Tan, Y., Hongfan, W., Gong, W., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00293-y · Cited by 14
A comprehensive review of the analysis and integration of omics data for SARS-CoV-2 and COVID-19
Zhu, Z., Zhang, S., Wang, P., Chen, X., Bi, J., Cheng, L., & Zhang, X. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab446 · Cited by 14
Hassanin, A. A., Raza, S. H. A., Ujan, J. A., ALrashidi, A. A., Sitohy, B., AL-surhanee, A. A., Saad, A. M., Al-Hazani, T. M. I., Atallah, O. O., Syaad, K. M. A., et al. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.12.020 · Cited by 14
Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes
Qian, Z., Li, P., Tang, X., & Lü, J. (2022) · Medical Review · doi:10.1515/mr-2021-0035 · Cited by 14
Ma, Q., Lei, B., Chen, R., Liu, B., Lu, W., Jiang, H., Chen, Z., Guo, X., Wang, Y., Zhang, L., et al. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00598-4 · Cited by 14
Lafuente‐Lafuente, C., Rainone, A., Guérin, O., Drunat, O., Jeandel, C., Hanon, O., Belmin, J., & for the C-VENH (COVID-19 Vaccine Effectiveness in Older Patients) Investigators (2022) · Gerontology · doi:10.1159/000523701 · Cited by 14
Zabaleta, N., Bhatt, U., Hérate, C., Maisonnasse, P., Sanmiguel, J. C., Diop, C. T., Castore, S., Estelien, R., Li, D., Dereuddre‐Bosquet, N., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.007 · Cited by 17
A random priming amplification method for whole genome sequencing of SARS-CoV-2 virus
Chrząstek, K., Tennakoon, C., Bialy, D., Freimanis, G., Flannery, J., & Shelton, H. A. (2022) · BMC Genomics · doi:10.1186/s12864-022-08563-z · Cited by 14
Ma, Y., Wang, Y., Dong, C., Gonzalez, G. X., Zhu, W., Kim, J., Wei, L., Kang, S., & Wang, B. (2022) · Small · doi:10.1002/smll.202200836 · Cited by 14
Sui, Y., Li, J., Andersen, H., Zhang, R., Prabhu, S. K., Hoang, T. N., Venzon, D. J., Cook, A., Brown, R., Teow, E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac091 · Cited by 15
Große, M., Setz, C., Rauch, P., Auth, J., Morokutti-Kurz, M., Temchura, V., & Schubert, U. (2022) · Viruses · doi:10.3390/v14071404 · Cited by 14
Zhao, F., Keating, C., Ozorowski, G., Shaabani, N., Francino-Urdaniz, I. M., Barman, S., Limbo, O., Burns, A., Zhou, P.-P., Ricciardi, M. J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104914 · Cited by 14
SARS-CoV-2 cell-to-cell spread occurs rapidly and is insensitive to antibody neutralizationPreprint
Jackson, L., Rodel, H. E., Hwa, S.-H., Cele, S., Ganga, Y., Tegally, H., Bernstein, M. P., Giandhari, J., COMMIT-KZN Team, Gosnell, B. I., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.01.446516 · Cited by 16
Moore, P. L., Moyo-Gwete, T., Hermanus, T., Kgagudi, P., Ayres, F., Makhado, Z., SADOFF, J. C., Gars, M. L., Roey, G. V., Crowther, C. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.09.447722 · Cited by 14
Self-citationFratev, F. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.04.471246 · Cited by 14
Structural Analysis of Spike Protein Mutations in the SARS-CoV-2 Theta (P.3) Variant
Bascos, N. A. D., Mirano‐Bascos, D., Abesamis, K. I. A., Bagoyo, C. S., Mallapre, O., & Saloma, C. P. (2021) · The Philippine journal of science · doi:10.56899/150.05.31 · Cited by 13
Kostaki, E. G., Tseti, I. K., Tsiodras, S., Pavlakis, G. N., Sfikakis, P. P., & Paraskevis, D. N. (2021) · Life · doi:10.3390/life11050375 · Cited by 13
Kim, B.-J., Jeong, H., Seo, H., Lee, M.-H., Shin, H. M., & Kim, B.-J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.712274 · Cited by 13
Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology
Ochola, L. B., Ogongo, P., Mbugua, S. M., Gitaka, J., & Suliman, S. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.10.005 · Cited by 13
Inhibition of Respiratory RNA Viruses by a Composition of Ionophoric Polyphenols with Metal Ions
Kreiser, T., Zaguri, D., Sachdeva, S., Zamostiano, R., Mograbi, J., Segal, D., Bacharach, E., & Gazit, E. (2022) · Pharmaceuticals · doi:10.3390/ph15030377 · Cited by 13
Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa
Okoh, O. S., Nii-Trebi, N. I., Jakkari, A., Olaniran, T. T., Senbadejo, T. Y., Kafintu-kwashie, A. A., Dairo, E. O., Ganiyu, T. O., Akaninyene, I. E., Ezediuno, L. O., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103880 · Cited by 13
Validation of a Saliva-Based Test for the Molecular Diagnosis of SARS-CoV-2 Infection
Bulfoni, M., Sozio, E., Marcon, B., Martino, M. D., Cesselli, D., Carlo, C. D., Martinella, R., Migotti, A., Vania, E., Zanus-Fortes, A., et al. (2022) · Disease Markers · doi:10.1155/2022/6478434 · Cited by 13
Evolutionary history of the SARS-CoV-2 Gamma variant of concern (P.1): a perfect storm
Yépez, Y., Marcano-Ruiz, M., Bezerra, R. S., Fam, B., Ximenez, J. P., Silva, W. A., Jr., & Bortolini, M. C. (2022) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2021-0309 · Cited by 15
Walters, J. N., Schouest, B., Patel, A. R., Reuschel, E. L., Schultheis, K., Parzych, E. M., Maricic, I., Gary, E. N., Purwar, M., Andrade, V. M., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.060 · Cited by 14
Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2
Burnouf, T., Gathof, B. S., Bloch, E. M., Bazin, R., Angelis, V. D., Patidar, G. K., Rastvorceva, R. M. G., Oreh, A. C., Goel, R., Rahimi‐Levene, N., et al. (2022) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2022.06.001 · Cited by 13
When Successive Viral Mutations Prevent Definitive Treatment of COVID-19
Mohammadi, M. R., & Sabati, H. (2022) · Cellular Molecular and Biomedical Reports · doi:10.55705/cmbr.2022.339012.1040 · Cited by 13
Chuang, S.-T., & Buchwald, P. (2022) · Pharmaceuticals · doi:10.3390/ph15091084 · Cited by 13
Simultaneous spectrofluorimetic determination of remdesivir and simeprevir in human plasma
Sharkasy, M. E. E., Tolba, M. M., Belal, F. F., Walash, M. I., & Aboshabana, R. (2022) · Scientific Reports · doi:10.1038/s41598-022-26559-3 · Cited by 13
Evolution of Sequence and Structure of SARS-CoV-2 Spike Protein: A Dynamic Perspective
Sinha, A., Sangeet, S., & Roy, S. (2023) · ACS Omega · doi:10.1021/acsomega.3c00944 · Cited by 14
Bui, N.-N., Lin, Y.-T., Huang, S.-H., & Lin, C. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.105164 · Cited by 13
Gobeil, P., Pillet, S., Boulay, I., Charland, N., Lorin, A., Cheng, M. P., Vinh, D. C., Boutet, P., der Most, R. G. V., Roman, F. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34728-1 · Cited by 13
Chang, X., Augusto, G. S., Liu, X., Kündig, T. M., Vogel, M., Mohsen, M. O., & Bachmann, M. F. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.13.435222 · Cited by 13
Kao, H., Orry, A. J. W., Palfreyman, M. G., & Porton, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-14194-x · Cited by 12
Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19
Chen, S., Zhang, C., Chen, D., Dong, L., Chang, T., & Tang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1200289 · Cited by 14
The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution
Liu, Y., & Ye, Q. (2023) · Vaccines · doi:10.3390/vaccines11091472 · Cited by 12
Volkan, E. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00353-4 · Cited by 12
Multi-Subunit SARS-CoV-2 Vaccine Design Using Evolutionarily Conserved T- and B- Cell Epitopes
Akbay, B., Abidi, S. H., Ibrahim, M. A. A., Mukhatayev, Z., & Ali, S. (2021) · Vaccines · doi:10.3390/vaccines9070702 · Cited by 12
Tracking down B.1.351 SARS‐CoV‐2 variant in Pakistan through genomic surveillance
Umair, M., Ikram, A., Badar, N., Haider, S. A., Rehman, Z., Ammar, M., Ahad, A., Ali, Q., Suleman, R., & Salman, M. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27328 · Cited by 12
COVID-19 vaccine candidates and vaccine development platforms available worldwide
Duman, N., Alzaidi, Z., Aynekin, B., Taskin, D., Demirors, B., Yildirim, A., Şahin, İ. O., Bilgili, F., Turanlı, E. T., Beccari, T., et al. (2021) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2021.09.004 · Cited by 12
A Potential Role of the CD47/SIRPalpha Axis in COVID-19 Pathogenesis
McLaughlin, K.-M., Bojková, D., Kandler, J. D., Bechtel, M., Reus, P., Le, T. T., Rothweiler, F., Wagner, J. U. G., Weigert, A., Ciesek, S., et al. (2021) · Current Issues in Molecular Biology · doi:10.3390/cimb43030086 · Cited by 13
Pan, T. S., Hu, Z., Hu, F., Zhang, Y., Liu, B., Ke, C., She, Q., He, X., Tang, X., & Zhang, H. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00776-8 · Cited by 12
Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models
Kim, Y., Casel, M. A. B., & Choi, Y. K. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-2033-z · Cited by 14
Scutt, G., Cross, M., & Waxman, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-12591-w · Cited by 12
da Silva, E. S., Kohnen, M., Gilson, G., Staub, T., Arendt, V., Hilger, C., Servais, J.-Y., Charpentier, É., Domingues, O., Snoeck, C. J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147675 · Cited by 12
Metadata
- Authors
- Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., Rossouw, T., Boswell, M., Ueckermann, V., Meiring, S., von Gottberg, A., Cohen, C., Morris, L., Bhiman, J. N., & Moore, P. L.
- Affiliations
- National Health Laboratory Service (ZA)
- South African National Blood Service (ZA)
- University of Pretoria (ZA)
- Steve Biko Hospital (ZA)
- Corresponding author
- Moore, Penny L.
- ORCID
- Venue
- Nature Medicine
- Published
- 2021-03-02
- Volume
- 27
- Issue
- 4
- Pages
- 622-625
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC7836116
- OpenAlex
- W3133794453
- Cited by
- 1,147
- References
- 38
- Citations by year
- 2026: 10 · 2025: 29 · 2024: 58 · 2023: 97 · 2022: 314 · 2021: 634
- FWCI
- 87.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature Medicine (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nd)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (submittedVersion, cc-by-nd)
- PubMed Central (submittedVersion, cc-by-nd)
- UpSpace Institutional Repository (University of Pretoria) (submittedVersion)
- Funders
- Wellcome Trust (221003/Z/20/Z, 221003)
- Government of the United Kingdom
- Royal Society
- National Research Foundation (98341)
- South African Medical Research Council (98341, SHIPNCD 76756, 96825)
- Department of Science and Technology, Ministry of Science and Technology, India
- African Academy of Sciences
- National Institutes of Health (98341, COVID-19)
- Centers for Disease Control and Prevention (5 U01IP001048-05-00, U01IP001048)
- Medical Research Council (COVID-19)
- Fogarty International Center (R21TW011454, D43TW010345)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- SARS-CoV-2, B.1.351 variant, spike protein mutations, antibody escape, neutralization, convalescent plasma, monoclonal antibodies, reinfection, vaccine efficacy, pseudovirus, spike protein binding
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
